Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Nabriva Therapeutics plc (NBRV)

1.88   0.04 (2.17%) 02-03 15:59
Open: 1.86 Pre. Close: 1.84
High: 1.94 Low: 1.8101
Volume: 32,807 Market Cap: 6(M)

Technical analysis

as of: 2023-02-03 3:49:26 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.77     One year: 3.24
Support: Support1: 1.66    Support2: 1.21
Resistance: Resistance1: 2.38    Resistance2: 2.77
Pivot: 1.59
Moving Average: MA(5): 1.71     MA(20): 1.55
MA(100): 2.2     MA(250): 5
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 91.4     %D(3): 91.7
RSI: RSI(14): 57.5
52-week: High: 13.37  Low: 0.17
Average Vol(K): 3-Month: 96 (K)  10-Days: 32 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NBRV ] has closed above the upper band by 5.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.9 - 1.91 1.91 - 1.91
Low: 1.75 - 1.76 1.76 - 1.77
Close: 1.83 - 1.84 1.84 - 1.85

Company Description

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Headline News

Tue, 31 Jan 2023
Do Traders Think Nabriva Therapeutics PLC - ADR (NBRV) Can Keep Climbing Tuesday? - InvestorsObserver

Tue, 10 Jan 2023
How Does Nabriva Therapeutics PLC - ADR (NBRV) Stock Rank on Wall Street Tuesday? - InvestorsObserver

Mon, 09 Jan 2023
Will Nabriva Therapeutics PLC - ADR (NBRV) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Fri, 06 Jan 2023
Should You Hold Nabriva Therapeutics PLC - ADR (NBRV) in Biotechnology Industry? - InvestorsObserver

Fri, 06 Jan 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average ... - Investing.com

Fri, 06 Jan 2023
Sector Update : Healthcare Stocks Rise Friday, Mostly Trail Other Sectors - Marketscreener.com

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 57 (M)
Shares Float 2 (M)
% Held by Insiders 0.5 (%)
% Held by Institutions 13.1 (%)
Shares Short 109 (K)
Shares Short P.Month 24 (K)

Stock Financials

EPS -5.41
EPS Est Next Qtl -0.5
EPS Est This Year -2.29
EPS Est Next Year -2
Book Value (p.s.) 1.57
Profit Margin (%) -132
Operating Margin (%) -129.3
Return on Assets (ttm) -38
Return on Equity (ttm) -89.9
Qtrly Rev. Growth 11.5
Gross Profit (p.s.) 0.05
Sales Per Share 0.62
EBITDA (p.s.) -0.8
Qtrly Earnings Growth 0
Operating Cash Flow -48 (M)
Levered Free Cash Flow -31 (M)

Stock Valuations

PE Ratio -0.35
PEG Ratio 0
Price to Book value 1.17
Price to Sales 2.97
Price to Cash Flow -2.18

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-12-02
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.